Jared Holz, Mizuho Securities healthcare sector specialist, joins ‘Fast Money’ to talk controversy brewing at Biogen, Alzheimer’s drug approval roadblocks in Europe, and more.
Biogen has been an ‘uninvestable’ stock for awhile, says Mizuho’s Jared Holz
June 14, 2023
